2016•Unpublished venueRequires access

Clinical and cost-effectiveness of beta interferon and glatiramer acetate for treating multiple sclerosis

G. J. Meléndez‐Torres, Peter Auguste, Xavier Armoiry, Hendramoorthy Maheswaran, R. Courtt, Jason Madan, A. Kanibolotsky, S. Lin, Carl Counsell, Jacoby Patterson, J. Rodrigus, Olga Ciccarelli, Aileen Clarke

Open publisher page 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Glatiramer acetate, Multiple sclerosis, Interferon beta-1b, Interferon beta, Medicine, BETA (programming language), Interferon, Interferon beta-1a

Back to paper search Browse research topics Original source

Clinical and cost-effectiveness of beta interferon and glatiramer acetate for treating multiple sclerosis — Research Paper | ScholarLens